Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Additional information

There are no experimental and/or literature specific data on L-CARNITINEAMIDE D-CAMPHORATED.

The analysis was carried out by calculation tools, but results were not exhaustive, since it is a salt, public programs are outside the application field and can not be used. Therefore it has been evaluated the comparison with the base (Camphor; CAS: 76 -22 -2; EC: 200 -945 -0) and the counter-ion(Levocarnitine; CAS: 541 -15 -1; EC: 208 -768 -0)of the substance, because the metabolism pathway of the substance is dissociate to its base and counter-ion, Camphor and Levocarnitine, and Camphor undergos to further transformation to Camphoric acid by ossidative metabolism.

Data available on Camphor [*-15, 16, 17] reported slight adverse effects at high dose administrated, while data available on Levocarnitine [*21, 22] do not report mutagenic affects.

In both cases substances are consider as NON mutagent agents and the L-Carnitineamide D-Champorated is not expected to be mutagen, too.

Any details about data available are reported in the report attached at the point 13: Assessment Report.


[*]Secondary source: Hazardous Substances Data Bank – HSDB - U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, National Institutes of Health, Department of Health & Human Services

[15] National Poisons Information Service Center, United Kingdom; Poisons Information Monograph: Camphor. (March 1996). Available from, as of February 6, 2004: **PEER REVIEWED**

[16] Goel HC et al; Mutat Res 224 (2): 157-60 (1989) **PEER REVIEWED**

[17] Gomes-Carneiro MR et al; Mutat Res 416 (1-2): 129-36 (1998) **PEER REVIEWED**

[21] Thorne Research, Inc.; Monograph on Acetyl-L-Carnitine; Alternative Medicine Review 4(6) p.439 (1999). Available from, as of February 26, 2008: **PEER REVIEWED**

[22] Thorne Research, Inc.; Monograph on L-Carnitine; Alternative Medicine Review 10(1) p.47 (2005). Available from, as of February 25, 2008: **PEER REVIEWED**

Short description of key information:
Non mutagen

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

Based on read across evaluation, the L-Carnitineanide D-Camphorated is not expected to be mutagen.

According to the Regulation EC 1272/2008 (CLP) L-Carnitineamide D-Camphorated is classified as non mutagen.